A Competitive Analysis of the Global Breast Cancer Therapeutics Market

A New Class of Targeted Therapeutics Offers Novel Treatment Modalities to Treat Difficult Breast Cancers

USD 4,950.00

* Required Fields

USD 4,950.00


Be the first to review this product

The study assesses marketed and investigational products and combination regimens for the global breast cancer therapeutics market. Segmentation by drug class is provided, along with supporting information, such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. Marketed and pipeline products are broadly segmented into hormonal therapy, targeted therapy, chemotherapy, and other therapies of current global interest. A large number of products in clinical development and the rising demand for breast cancer therapeutics are the key market drivers.

Table of Contents

Executive SummaryExecutive SummaryExecutive Summary (continued)Physician Guidelines to Breast Cancer Therapy—Her 2 PositivePhysician Guidelines to Breast Cancer Therapy—ER or PR PositivePhysician Guidelines to Breast Cancer Therapy—Triple-negative Breast CancerKey TrendsMarket OpportunitiesCompanies to WatchExecutive SummaryMethodology and ScopeMarket OverviewMarket Overview—IntroductionMarket Overview—Introduction (continued)Market Overview—Incidence Rate of Breast CancerMarket SizeMarket SegmentationCompetitive Landscape—Breast Cancer Marketed Products and Pipeline CandidatesCompetitive Landscape OverviewCompetitive Landscape—Breast Cancer Marketed and Pipeline ProductsMarketed Products—Hormone TherapyMarketed Products—Hormone Therapy (continued)Pipeline Products—Hormone Therapy (continued)Marketed Products—Targeted TherapyPipeline Products—Targeted Therapy (continued)Pipeline Products—Targeted Therapy (continued)Marketed Products—ChemotherapyMarketed Products—Chemotherapy (continued)Pipeline Products—ChemotherapyPipeline Products—Other TherapiesProduct Launch TimelinePatent ExpirationsPivotal Phase 3 TrialsBreast Cancer Therapeutics—Major Ongoing/Recently Completed Clinical TrialsBreast Cancer Therapeutics—Major Ongoing/Recently Completed Clinical Trials (continued)Breast Cancer Therapeutics—Major Ongoing/Recently Completed Clinical Trials (continued)Summary of Key Products to WatchProduct Dashboard (Marketed Products and Phase 3 Candidates)Product Dashboard—Herceptin (Trastuzumab)Product Dashboard—Afinitor (Everolimus)Product Dashboard—Arimidex (Anastrozole)Product Dashboard—Perjeta (Pertuzumab)Product Dashboard—Tykerb (Lapatinib)Product Dashboard—Taxol (Paclitaxel)Product Dashboard—Xeloda (Capecitabine)Product Dashboard—Kadcyla (Ado-trastuzumab emtansine)Product Dashboard—PD-0332991(Palbociclib)Product Dashboard—NeuVax (Nelipepimut-S)ConclusionsConclusionsLegal DisclaimerAppendixDecision Support DatabaseDecision Support Database (continued)Decision Support Database (continued)The Frost & Sullivan StoryThe Frost & Sullivan StoryValue PropositionGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.